CARBACEPHEM BETA-LACTAM ANTIBIOTICS
    5.
    发明申请
    CARBACEPHEM BETA-LACTAM ANTIBIOTICS 审中-公开
    CARBACEPHEM BETA-LACTAM抗生素

    公开(公告)号:WO2010030810A1

    公开(公告)日:2010-03-18

    申请号:PCT/US2009/056554

    申请日:2009-09-10

    CPC分类号: C07D463/22

    摘要: Carbacephem β-lactam antibiotics having structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar 2 , X, R 1 and R 2 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.

    摘要翻译: 公开了具有结构(I)的碳纤维β-内酰胺抗生素,包括立体异构体,其药学上可接受的盐,酯和前药,其中Ar 2,X,R 1和R 2如本文所定义。 这些化合物可用于治疗细菌感染,特别是由耐甲氧西林葡萄球菌引起的细菌感染。

    2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE DERIVATIVES
    8.
    发明申请
    2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE DERIVATIVES 审中-公开
    2'-取代的核苷酸和寡核苷酸衍生物

    公开(公告)号:WO1997046569A2

    公开(公告)日:1997-12-11

    申请号:PCT/EP1997002738

    申请日:1997-05-27

    发明人: NOVARTIS AG

    IPC分类号: C07H21/00

    CPC分类号: C07H21/00

    摘要: The invention relates to an oligonucleotide derivative which comprises at least one nucleoside building block of the formula (I). The invention furthermore relates to nucleoside building blocks, intermediates and processes for preparing the oligonucleotide derivatives and the nucleoside building blocks. The invention also relates to pharmaceutical compositions and to uses of the oligonucleotide derivatives and the nucleoside building blocks.

    摘要翻译: 本发明涉及包含至少一种式(I)核苷结构单元的寡核苷酸衍生物。 本发明还涉及用于制备寡核苷酸衍生物和核苷结构单元的核苷结构单元,中间体和方法。 本发明还涉及药物组合物以及寡核苷酸衍生物和核苷结构单元的用途。

    FUNCTIONAL TERPYRIDINE METAL COMPLEXES, METHODS FOR THEIR PREPARATION AND OLIGONUCLEOTIDE CONJUGATES WITH TERPYRIDINE METAL COMPLEXES
    9.
    发明申请
    FUNCTIONAL TERPYRIDINE METAL COMPLEXES, METHODS FOR THEIR PREPARATION AND OLIGONUCLEOTIDE CONJUGATES WITH TERPYRIDINE METAL COMPLEXES 审中-公开
    功能三联吡啶金属络合物用于生产和寡核苷酸缀合物金属配合物三联吡啶

    公开(公告)号:WO1996007668A1

    公开(公告)日:1996-03-14

    申请号:PCT/EP1995003409

    申请日:1995-08-30

    发明人: CIBA-GEIGY AG

    IPC分类号: C07H21/00

    摘要: Disclosed are compounds of formula (V), wherein R2 and R7, independently of each other, are H, C1-C4 alkyl, C1-C4 alkoxy, C7-C12 aralkyl, C6-C16 aryl or halogen; R3 and R6, independently of each other, are H, C1-C4 alkyl, C7-C12 aralkyl or C6-C16 aryl; R4 is H, C1-C20 alkyl, C5-C8 cycloalkyl, C6-C12 aryl or C7-C12 aralkyl, the alkyl, cycloalkyl, aralkyl and aryl radicals being unsubstituted or substituted with C1-C4 alkoxy, F, Cl, Br, -CN, C1-C4 alkyl or -NO2; Me is a lanthanide metal or yttrium; Y is an anion of an acid; n stands for 2 or 3 and m is 1, 2 or 3; R9 is a radical of formula (VI) -Xp-A-X'q-A'r-Oligo, and R8 is H, C1-C4 alkyl, C1-C4 alkoxy, C7-C12 aralkyl, C6-C16 aryl, or R9 is H, C1-C4 alkyl, C1-C4 alkoxy, C7-C12 aralkyl, C6-C16 aryl and R8 is a radical of formula (VI); p, q and r, independently of one another, are 0 or 1; X and X', independently of each other, are a radical unsubstituted or substituted by C1-C4 alkoxy, F, Cl, Br, -CN, C1-C4 alkyl or -NO2 substituted radical selected from the group consisting of C1-C20 alkylene, C2-C12 alkenylene, C2-C12 alkinylene, -(CxH2xO)y-, wherein x equals a number from 2 to 6 and y equals a number from 1 to 20, C5-C8 cycloalkylene, C6-C12 arylene and C7-C12 aralkylene; A and A', independently of each other, are -O-, -S-, -S-S-, -NR12-CO-NR12-CO-NR12-, -NR12-CS-NR12-, -NR12-, -NR12-C(O)-O-, -C(O)O-, -C(O)S-, -C(O)NR12-, -C(S)S-, -C(S)O-, -C(S)NR12-, -SO2NR12-, -SO2-, -P(O)(OH)O-, P(S)(SH)S-, -P(S)(SH)O-, -P(S)(OH)O-, -P(O)(SH)S-, -P(O)(OH)S-, -P(O)(SH)O-, -P(O)(OH)-NR12-, -P(S)(SH)-NR12-, -P(S)(OH)-NR12-, -P(O)(SH)-NR12-, -HP(O)O-, -HP(S)S-, -HP(O)NR12- or -HP(S)NR12-, R12 being H or C1-C6 alkyl; and oligo is a natural, modified or synthetic sequence of natural, modified or synthetic deoxynucleosides or peptide nucleic acid units which are bonded via a nucleic base, an internucleotide bridge or a sugar and whose inner region is complementary to a target RNA.

    摘要翻译: 式(V)其中R 2和R 7独立地表示H,C1-C4烷基C1-C4烷氧基,C7-C12芳烷基,C6-C16芳基或卤素的化合物,R 3和R 6独立地为H,C1 -C4烷基,C7-C12芳烷基,或C6-C16芳基,R 4为H,C1-C20烷基,C5-C8环烷基,C6-C12芳基或C7-C12芳烷基,其中所述基团 烷基,环烷基,芳烷基和芳基未被取代或者被C1-C4烷氧基取代,F,氯,溴,-CN,C1-C4烷基或-NO 2,Me是镧系金属或钇,Y是酸的阴离子 中,n是数字2或3,和m是数字1,2或3,R 9为下式基团的(VI)-XP-A-X'Q-A'r低聚,且R 8为H,C1 -C4-烷基是指C1-C4烷氧基,C7-C12芳烷基,或C6-C16芳基,或R 9是H,C1-C4烷基,C1-C4烷氧基,C7-C12芳烷基,或C6-C16 芳基和R 8是下式基团(VI)中,p,q和r是独立地0或1,X和X“独立地代表未取代的 或取代的基团C 1 -C 4 - 烷氧基,氟,氯,溴,-CN,C1-C4烷基或-NO 2选自C1-C20亚烷基,C2-C12烯基,C2-C12亚炔基中选择 , - (CX H2X O)y表示,其中x是一个从2到6和y是数字从1至20,C 5 -C 8亚环烷基,C6-C12亚芳基和C7-C12-亚芳烷基的意思是,一和 “独立地为-O - , - S - , - SS - , - NR 12 -CO--NR 12 - ,-NR 12 CS -NR 12 - , - NR 12,-NR 12 C(O)-O-,-C(O )O-,-C(O)S - , - C(O)-NR 12 - , - C(S)S - , - C(S)O - ,-C(S)-NR 12 - ,-SO2NR12-​​, - SO2- - ,-P(O)(OH)O - ,-P(S)(SH)S - ,-P(S)(SH)O-,-P(S)(OH)O-,-P(O )(SH)S - ,-P(O)(OH)-S-,-P(O)(SH)O-,-P(O)(OH)-NR 12,-P(S)(SH) - -NR 12 - ,-P(S)(OH)-NR 12,-P(O)(SH)-NR 12,-HP(O)O-,-HP(S)S - ,-HP(O)-NR 12 - 或-HP(S)-NR 12 - 平均,其中R12是H或C1-C6烷基; 和低聚是自然一个天然的,改性的或合成的序列,修饰或经由核酸碱,internucleotidic桥或糖和内部区域结合的合成的脱氧核苷或肽核酸构件是与靶RNA互补。

    CARBACEPHEM ß-LACTAM ANTIBIOTICS
    10.
    发明申请
    CARBACEPHEM ß-LACTAM ANTIBIOTICS 审中-公开
    CARBACEPHEMβ-内酰胺抗生素

    公开(公告)号:WO2010030811A3

    公开(公告)日:2010-08-12

    申请号:PCT/US2009056555

    申请日:2009-09-10

    CPC分类号: C07D463/22

    摘要: Carbacephem -lactam antibiotics having structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar1, Ar2, R1 and R2 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.

    摘要翻译: 公开了具有结构(I)的碳水化合物 - 内酰胺抗菌素,包括其立体异构体,药学上可接受的盐,酯和前药,其中Ar 1,Ar 2,R 1和R 2如本文所定义。 该化合物可用于治疗细菌感染,特别是由耐甲氧西林葡萄球菌属引起的感染。